Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says
Publishing timestamp: 2023-04-25 16:21:41
Summary
Bavarian Nordic plans to increase production capacity for its Jynneos vaccine, which is approved by the FDA to protect against both monkeypox and smallpox. The company aims to simplify its production process and partner with other manufacturers to scale up production capacity to hundreds of millions of doses in the event of an emergency. The recent outbreak of monkeypox was a wake-up call for the company to prepare for a potential smallpox threat. While smallpox was eradicated in 1980, there are still two known stockpiles of the virus, and some governments are interested in stockpiling Jynneos for use against smallpox. The current production capacity of Jynneos is tens of millions of doses, which would not be sufficient for a widespread outbreak of smallpox.
Sentiment: NEUTRAL
Keywords: epidemics, bavarian nordic a/s, disease outbreaks, biotech and pharmaceuticals, pandemics, business, smallpox, health care industry, business news, environment, united states, mpox, biotechnology, coronavirus,
Source: https://www.cnbc.com/2023/04/25/mpox-shows-smallpox-risk-vaccine-maker-bavarian-nordic-says.html